Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Povetacicept in primary membranous nephropathy
NL-OMON59780Phase 3Not yet recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jul 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of povetacicept in idiopathic membranous glomerulonephritis (IMG), sponsored by Vertex Pharmaceuticals. Primary endpoint: Proportion of participants with Complete Clinical Remission Definition 1 (CR1). Planned start Jul 2026; status: not yet recruiting.
02
Drugs
povetacicept
03
Conditions
idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on NL-OMON59780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59780.